HIV-associated lung disease.
Journal
Nature reviews. Disease primers
ISSN: 2056-676X
Titre abrégé: Nat Rev Dis Primers
Pays: England
ID NLM: 101672103
Informations de publication
Date de publication:
27 07 2023
27 07 2023
Historique:
accepted:
19
06
2023
medline:
31
7
2023
pubmed:
28
7
2023
entrez:
27
7
2023
Statut:
epublish
Résumé
Lung disease encompasses acute, infectious processes and chronic, non-infectious processes such as chronic obstructive pulmonary disease, asthma and lung cancer. People living with HIV are at increased risk of both acute and chronic lung diseases. Although the use of effective antiretroviral therapy has diminished the burden of infectious lung disease, people living with HIV experience growing morbidity and mortality from chronic lung diseases. A key risk factor for HIV-associated lung disease is cigarette smoking, which is more prevalent in people living with HIV than in uninfected people. Other risk factors include older age, history of bacterial pneumonia, Pneumocystis pneumonia, pulmonary tuberculosis and immunosuppression. Mechanistic investigations support roles for aberrant innate and adaptive immunity, local and systemic inflammation, oxidative stress, altered lung and gut microbiota, and environmental exposures such as biomass fuel burning in the development of HIV-associated lung disease. Assessment, prevention and treatment strategies are largely extrapolated from data from HIV-uninfected people. Smoking cessation is essential. Data on the long-term consequences of HIV-associated lung disease are limited. Efforts to continue quantifying the effects of HIV infection on the lung, especially in low-income and middle-income countries, are essential to advance our knowledge and optimize respiratory care in people living with HIV.
Identifiants
pubmed: 37500684
doi: 10.1038/s41572-023-00450-5
pii: 10.1038/s41572-023-00450-5
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
39Subventions
Organisme : NIAID NIH HHS
ID : U01 AI103390
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146194
Pays : United States
Informations de copyright
© 2023. Springer Nature Limited.
Références
Masur, H. et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N. Engl. J. Med. 305, 1431–1438 (1981).
pubmed: 6975437
doi: 10.1056/NEJM198112103052402
Palella, F. J. et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338, 853–860 (1998).
pubmed: 9516219
doi: 10.1056/NEJM199803263381301
Weverling, G. J. et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. Lancet 353, 1293–1298 (1999).
pubmed: 10218526
doi: 10.1016/S0140-6736(99)03287-0
Gingo, M. R. et al. The impact of HAART on the respiratory complications of HIV infection: longitudinal trends in the MACS and WIHS cohorts. PLoS ONE 8, e58812 (2013).
pubmed: 23554932
pmcid: 3595204
doi: 10.1371/journal.pone.0058812
Segal, L. N. et al. HIV-1 and bacterial pneumonia in the era of antiretroviral therapy. Proc. Am. Thorac. Soc. 8, 282–287 (2011).
pubmed: 21653529
pmcid: 3132786
doi: 10.1513/pats.201006-044WR
SeyedAlinaghi, S. et al. COVID-19 mortality in patients with immunodeficiency and its predictors: a systematic review. Eur. J. Med. Res. 27, 195 (2022).
pubmed: 36209202
pmcid: 9547631
doi: 10.1186/s40001-022-00824-7
Gingo, M. R., Morris, A. & Crothers, K. Human immunodeficiency virus-associated obstructive lung diseases. Clin. Chest Med. 34, 273–282 (2013).
pubmed: 23702176
pmcid: 3690924
doi: 10.1016/j.ccm.2013.02.002
Gingo, M. R. et al. Asthma diagnosis and airway bronchodilator response in HIV-infected patients. J. Allergy Clin. Immunol. 129, 708–714.e8 (2012).
pubmed: 22177327
doi: 10.1016/j.jaci.2011.11.015
Drummond, M. B. et al. Association between HIV and prevalence and manifestations of asthma: analysis of the Multicenter AIDS Cohort Study and Women’s Interagency HIV Study. J. Acquir. Immune Defic. Syndr. https://doi.org/10.1097/QAI.0000000000003088 (2022).
doi: 10.1097/QAI.0000000000003088
pubmed: 36083508
pmcid: 8647697
World Health Organization. World Health Statistics 2022: Monitoring Health for the SDGs, Sustainable Development Goals (WHO, 2022).
Crothers, K. et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am. J. Respir. Crit. Care Med. 183, 388–395 (2011).
pubmed: 20851926
pmcid: 3266024
doi: 10.1164/rccm.201006-0836OC
Phair, J. et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N. Engl. J. Med. 322, 161–165 (1990).
pubmed: 1967190
doi: 10.1056/NEJM199001183220304
Stansell, J. D. et al. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary complications of HIV Infection Study Group. Am. J. Respir. Crit. Care Med. 155, 60–66 (1997).
pubmed: 9001290
doi: 10.1164/ajrccm.155.1.9001290
Horsburgh, C. R. Priorities for the treatment of latent tuberculosis infection in the United States. N. Engl. J. Med. 350, 2060–2067 (2004).
pubmed: 15141044
doi: 10.1056/NEJMsa031667
Andrews, J. R. et al. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin. Infect. Dis. 54, 784–791 (2012).
pubmed: 22267721
pmcid: 3284215
doi: 10.1093/cid/cir951
Sloot, R. S., van der Loeff, M. F., Kouw, P. M. & Borgdorff, M. W. Risk of tuberculosis after recent exposure. A 10-year follow-up study of contacts in Amsterdam. Am. J. Respir. Crit. Care Med. 190, 1044–1052 (2014).
pubmed: 25265362
doi: 10.1164/rccm.201406-1159OC
Menzies, N. A. et al. Time since infection and risks of future disease for individuals with Mycobacterium tuberculosis infection in the United States. Epidemiology 32, 70–78 (2021).
pubmed: 33009253
doi: 10.1097/EDE.0000000000001271
Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Clinical Info HIV.gov https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection (2023).
World Health Organization. Global tuberculosis report 2022. WHO https://www.who.int/publications/i/item/9789240061729 (2022).
Hirschtick, R. E. et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N. Engl. J. Med. 333, 845–851 (1995).
pubmed: 7651475
doi: 10.1056/NEJM199509283331305
Kohli, R. et al. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV Epidemiologic Research (HER) study. Clin. Infect. Dis. 43, 90–98 (2006).
pubmed: 16758423
doi: 10.1086/504871
Balakrishna, S. et al. Decreasing incidence and determinants of bacterial pneumonia in people with HIV: the Swiss HIV Cohort Study. J. Infect. Dis. https://doi.org/10.1093/infdis/jiab573 (2021).
doi: 10.1093/infdis/jiab573
Mussini, C. et al. Incidence, timing, and determinants of bacterial pneumonia among HIV-infected patients: data from the ICONA Foundation Cohort. J. Acquir. Immune Defic. Syndr. 63, 339–345 (2013).
pubmed: 23591636
doi: 10.1097/QAI.0b013e318295ab85
Sullivan, J. H., Moore, R. D., Keruly, J. C. & Chaisson, R. E. Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. Am. J. Respir. Crit. Care Med. 162, 64–67 (2000).
pubmed: 10903221
doi: 10.1164/ajrccm.162.1.9904101
Bénard, A. et al. Bacterial pneumonia among HIV-infected patients: decreased risk after tobacco smoking cessation. ANRS CO3 Aquitaine Cohort, 2000-2007. PLoS ONE 5, e8896 (2010).
pubmed: 20126646
pmcid: 2811185
doi: 10.1371/journal.pone.0008896
Kaplan, J. E., Hanson, D. L., Navin, T. R. & Jones, J. L. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. J. Infect. Dis. 178, 1126–1132 (1998).
pubmed: 9806044
doi: 10.1086/515658
Wood, R., Maartens, G. & Lombard, C. J. Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J. Acquir. Immune Defic. Syndr. 23, 75–80 (2000).
pubmed: 10708059
doi: 10.1097/00126334-200001010-00010
Girardi, E. et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS 14, 1985–1991 (2000).
pubmed: 10997404
doi: 10.1097/00002030-200009080-00015
Girardi, E. et al. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin. Infect. Dis. 41, 1772–1782 (2005).
pubmed: 16288403
doi: 10.1086/498315
Severe, P. et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N. Engl. J. Med. 363, 257–265 (2010).
pubmed: 20647201
pmcid: 3676927
doi: 10.1056/NEJMoa0910370
Badri, M., Wilson, D. & Wood, R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 359, 2059–2064 (2002).
pubmed: 12086758
doi: 10.1016/S0140-6736(02)08904-3
del Amo, J. et al. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Clin. Infect. Dis. 54, 1364–1372 (2012).
pubmed: 22460971
doi: 10.1093/cid/cis203
Gordin, F. M. et al. Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption. Am. J. Respir. Crit. Care Med. 178, 630–636 (2008).
pubmed: 18617640
pmcid: 2542436
doi: 10.1164/rccm.200804-617OC
Mdodo, R. et al. Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys. Ann. Intern. Med. 162, 335–344 (2015).
pubmed: 25732274
doi: 10.7326/M14-0954
Mdege, N. D., Shah, S., Ayo-Yusuf, O. A., Hakim, J. & Siddiqi, K. Tobacco use among people living with HIV: analysis of data from demographic and health surveys from 28 low-income and middle-income countries. Lancet Glob. Health 5, e578–e592 (2017).
pubmed: 28495263
pmcid: 5439027
doi: 10.1016/S2214-109X(17)30170-5
Pacek, L. R. & Crum, R. M. A review of the literature concerning HIV and cigarette smoking: morbidity and mortality, associations with individual- and social-level characteristics, and smoking cessation efforts. Addict. Res. Theory 23, 10–23 (2015).
pubmed: 28529471
doi: 10.3109/16066359.2014.920013
Helleberg, M. et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin. Infect. Dis. 56, 727–734 (2013).
pubmed: 23254417
doi: 10.1093/cid/cis933
Cornelius, M. E., Wang, T. W., Jamal, A., Loretan, C. G. & Neff, L. J. Tobacco product use among adults – United States, 2019. Morb. Mortal. Wkly Rep. 69, 1736–1742 (2020).
doi: 10.15585/mmwr.mm6946a4
Asfar, T. et al. National estimates of prevalence, time-trend, and correlates of smoking in US people living with HIV (NHANES 1999-2016). Nicotine Tob. Res. 23, 1308–1317 (2021).
pubmed: 33856483
pmcid: 8517967
doi: 10.1093/ntr/ntaa277
Murphy, J. D., Liu, B. & Parascandola, M. Smoking and HIV in sub-Saharan Africa: a 25-country analysis of the demographic health surveys. Nicotine Tob. Res. 21, 1093–1102 (2019).
pubmed: 30165688
doi: 10.1093/ntr/nty176
Bigna, J. J., Kenne, A. M., Asangbeh, S. L. & Sibetcheu, A. T. Prevalence of chronic obstructive pulmonary disease in the global population with HIV: a systematic review and meta-analysis. Lancet Glob. Health 6, e193–e202 (2018).
pubmed: 29254748
doi: 10.1016/S2214-109X(17)30451-5
Brown, J. et al. Respiratory health status is impaired in UK HIV-positive adults with virologically suppressed HIV infection. HIV Med. 18, 604–612 (2017).
pubmed: 28294498
doi: 10.1111/hiv.12497
Madeddu, G. et al. Chronic obstructive pulmonary disease: an emerging comorbidity in HIV-infected patients in the HAART era? Infection 41, 347–353 (2013).
pubmed: 22971938
doi: 10.1007/s15010-012-0330-x
Ronit, A. et al. Airflow limitation in people living with HIV and matched uninfected controls. Thorax 73, 431–438 (2018).
pubmed: 29331988
doi: 10.1136/thoraxjnl-2017-211079
Makinson, A. et al. HIV is associated with airway obstruction: a matched controlled study. AIDS 32, 227–232 (2018).
pubmed: 29135582
doi: 10.1097/QAD.0000000000001691
Verboeket, S. O. et al. Reduced forced vital capacity among human immunodeficiency virus-infected middle-aged individuals. J. Infect. Dis. 219, 1274–1284 (2019).
pubmed: 30418599
doi: 10.1093/infdis/jiy653
Cui, Q. et al. Effect of smoking on lung function, respiratory symptoms and respiratory diseases amongst HIV-positive subjects: a cross-sectional study. AIDS Res. Ther. 7, 6 (2010).
pubmed: 20298614
pmcid: 2853483
doi: 10.1186/1742-6405-7-6
Crothers, K. et al. HIV infection is associated with reduced pulmonary diffusing capacity. J. Acquir. Immune Defic. Syndr. 64, 271–278 (2013).
pubmed: 23979001
doi: 10.1097/QAI.0b013e3182a9215a
Fitzpatrick, M. E. et al. Novel relationships of markers of monocyte activation and endothelial dysfunction with pulmonary dysfunction in HIV-infected persons. AIDS 30, 1327–1339 (2016).
pubmed: 26990629
doi: 10.1097/QAD.0000000000001092
Wang, R. J. et al. Lung function in women with and without HIV. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciac391 (2022).
doi: 10.1093/cid/ciac391
pubmed: 35833899
pmcid: 10319953
Kunisaki, K. M. et al. Lung function in men with and without HIV. AIDS 34, 1227–1235 (2020).
pubmed: 32287070
doi: 10.1097/QAD.0000000000002526
Nakamura, H. et al. The prevalence of airway obstruction among Japanese HIV-positive male patients compared with general population; a case-control study of single center analysis. J. Infect. Chemother. 20, 361–364 (2014).
pubmed: 24661405
doi: 10.1016/j.jiac.2014.02.001
van den Berg, O. E. et al. The influence of HIV infection and antiretroviral treatment on pulmonary function in individuals in an urban setting in sub-Saharan Africa. South. Afr. J. HIV Med. 22, 1312 (2021).
pubmed: 34858656
pmcid: 8603101
Varkila, M. R. J. et al. The association between HIV infection and pulmonary function in a rural African population. PLoS ONE 14, e0210573 (2019).
pubmed: 30645622
pmcid: 6333365
doi: 10.1371/journal.pone.0210573
Zifodya, J. S. et al. HIV, pulmonary infections, and risk of chronic lung disease among Kenyan adults. Ann. Am. Thorac. Soc. 18, 2090–2093 (2021).
pubmed: 34237231
pmcid: 8641811
doi: 10.1513/AnnalsATS.202103-251RL
Pefura-Yone, E. W., Fodjeu, G., Kengne, A. P., Roche, N. & Kuaban, C. Prevalence and determinants of chronic obstructive pulmonary disease in HIV infected patients in an African country with low level of tobacco smoking. Respir. Med. 109, 247–254 (2015).
pubmed: 25538018
doi: 10.1016/j.rmed.2014.12.003
van Gemert, F. et al. Prevalence of chronic obstructive pulmonary disease and associated risk factors in Uganda (FRESH AIR Uganda): a prospective cross-sectional observational study. Lancet Glob. Health 3, e44–e51 (2015).
pubmed: 25539969
doi: 10.1016/S2214-109X(14)70337-7
North, C. M. et al. HIV infection, pulmonary tuberculosis, and COPD in rural Uganda: a cross-sectional study. Lung 196, 49–57 (2018).
pubmed: 29260309
doi: 10.1007/s00408-017-0080-8
Risso, K. et al. COPD in HIV-infected patients: CD4 cell count highly correlated. PLoS ONE 12, e0169359 (2017).
pubmed: 28056048
pmcid: 5215875
doi: 10.1371/journal.pone.0169359
Sampériz, G. et al. Prevalence of and risk factors for pulmonary abnormalities in HIV-infected patients treated with antiretroviral therapy. HIV Med. 15, 321–329 (2014).
pubmed: 24314004
doi: 10.1111/hiv.12117
Costiniuk, C. T. et al. Prevalence and predictors of airflow obstruction in an HIV tertiary care clinic in Montreal, Canada: a cross-sectional study. HIV Med. 20, 192–201 (2019).
pubmed: 30620136
pmcid: 6590155
doi: 10.1111/hiv.12699
Gingo, M. R. et al. Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era. Am. J. Respir. Crit. Care Med. 182, 790–796 (2010).
pubmed: 20522793
pmcid: 2949404
doi: 10.1164/rccm.200912-1858OC
Drummond, M. B. et al. Factors associated with abnormal spirometry among HIV-infected individuals. AIDS 29, 1691–1700 (2015).
pubmed: 26372280
doi: 10.1097/QAD.0000000000000750
Drummond, M. B. et al. Association between obstructive lung disease and markers of HIV infection in a high-risk cohort. Thorax 67, 309–314 (2012).
pubmed: 22090038
doi: 10.1136/thoraxjnl-2011-200702
Gupte, A. N. et al. Factors associated with pulmonary impairment in HIV-infected South African adults. PLoS ONE 12, e0184530 (2017).
pubmed: 28902919
pmcid: 5597201
doi: 10.1371/journal.pone.0184530
Akanbi, M. O. et al. HIV associated chronic obstructive pulmonary disease in Nigeria. J. AIDS Clin. Res. 6, 453 (2015).
pubmed: 26236557
pmcid: 4521629
doi: 10.4172/2155-6113.1000453
Kayongo, A. et al. Chronic obstructive pulmonary disease prevalence and associated factors in a setting of well-controlled HIV, a cross-sectional study. J. COPD 17, 297–305 (2020).
doi: 10.1080/15412555.2020.1769583
Ddungu, A. et al. Chronic obstructive pulmonary disease prevalence and associated factors in an urban HIV clinic in a low income country. PLoS ONE 16, e0256121 (2021).
pubmed: 34388209
pmcid: 8362990
doi: 10.1371/journal.pone.0256121
Drummond, M. B. et al. The effect of HIV infection on longitudinal lung function decline among IDUs: a prospective cohort. AIDS 27, 1303–1311 (2013).
pubmed: 23299176
doi: 10.1097/QAD.0b013e32835e395d
Grigsby, M. et al. Socioeconomic status and COPD among low- and middle-income countries. Int. J. Chron. Obstruct. Pulmon. Dis. 11, 2497–2507 (2016).
pubmed: 27785006
pmcid: 5065097
doi: 10.2147/COPD.S111145
Gershon, A. S., Dolmage, T. E., Stephenson, A. & Jackson, B. Chronic obstructive pulmonary disease and socioeconomic status: a systematic review. J. COPD 9, 216–226 (2012).
doi: 10.3109/15412555.2011.648030
Pathak, U., Gupta, N. C. & Suri, J. C. Risk of COPD due to indoor air pollution from biomass cooking fuel: a systematic review and meta-analysis. Int. J. Environ. Health Res. 30, 75–88 (2020).
pubmed: 30754998
doi: 10.1080/09603123.2019.1575951
Park, J., Kim, H.-J., Lee, C.-H., Lee, C. H. & Lee, H. W. Impact of long-term exposure to ambient air pollution on the incidence of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Environ. Res. 194, 110703 (2021).
pubmed: 33417909
doi: 10.1016/j.envres.2020.110703
Ronit, A. et al. Incidence of chronic obstructive pulmonary disease in people with HIV, their parents and siblings in Denmark. J. Infect. Dis. https://doi.org/10.1093/infdis/jiab369 (2021).
doi: 10.1093/infdis/jiab369
pubmed: 34192319
Verboeket, S. O. et al. Changes in lung function among treated HIV-positive and HIV-negative individuals: analysis of the prospective AGEhIV cohort study. Lancet Healthy Longev. 2, e202–e211 (2021).
pubmed: 36098121
doi: 10.1016/S2666-7568(21)00033-7
Thudium, R. F. et al. Faster lung function decline in people living with HIV despite adequate treatment: a longitudinal matched cohort study. Thorax https://doi.org/10.1136/thorax-2022-218910 (2023).
doi: 10.1136/thorax-2022-218910
pubmed: 36639241
Depp, T. B. et al. Risk factors associated with acute exacerbation of chronic obstructive pulmonary disease in HIV-infected and uninfected patients. AIDS 30, 455–463 (2016).
pubmed: 26765938
Lambert, A. A. et al. HIV infection is associated with increased risk for acute exacerbation of COPD. J. Acquir. Immune Defic. Syndr. 69, 68–74 (2015).
pubmed: 25942460
pmcid: 4422097
doi: 10.1097/QAI.0000000000000552
Gingo, M. R. et al. Decreased lung function and all-cause mortality in HIV-infected individuals. Ann. Am. Thorac. Soc. 15, 192–199 (2018).
pubmed: 29313714
pmcid: 5822404
doi: 10.1513/AnnalsATS.201606-492OC
Triplette, M. et al. Markers of chronic obstructive pulmonary disease are associated with mortality in people living with HIV. AIDS 32, 487–493 (2018).
pubmed: 29135579
doi: 10.1097/QAD.0000000000001701
Kalmin, M. M. et al. Incident obstructive lung disease and mortality among HIV-positive and negative persons with a history of injecting drugs. AIDS https://doi.org/10.1097/QAD.0000000000002914 (2021).
doi: 10.1097/QAD.0000000000002914
pubmed: 33831913
Petoumenos, K. et al. Prevalence of self-reported comorbidities in HIV positive and HIV negative men who have sex with men over 55 years – the Australian Positive & Peers Longevity Evaluation Study (APPLES). PLoS ONE 12, e0184583 (2017).
pubmed: 28886173
pmcid: 5590989
doi: 10.1371/journal.pone.0184583
Rosen, M. J. et al. Pulmonary function tests in HIV-infected patients without AIDS. Pulmonary Complications of HIV Infection Study Group. Am. J. Respir. Crit. Care Med. 152, 738–745 (1995).
pubmed: 7633736
doi: 10.1164/ajrccm.152.2.7633736
Yano, C. et al. Airway hyperresponsiveness and inflammation in Japanese patients with human immunodeficiency virus 1 infection. J. Infect. Chemother. 28, 426–433 (2022).
pubmed: 34933786
doi: 10.1016/j.jiac.2021.12.001
Kheaw-on, N. et al. Bronchial hyperresponsiveness in HIV patients with CD4 count less than 500 cells/μL. Asian Biomed. 3, 255–260 (2009).
Kummerow, M. et al. Unexpected low frequency of respiratory symptoms in an HIV-positive urban sub-Saharan population compared to an HIV-negative control group. South. Afr. J. HIV Med. 20, 1010 (2019).
pubmed: 31616576
pmcid: 6779989
doi: 10.4102/sajhivmed.v20i1.1010
Kirenga, B. J. et al. The impact of HIV on the prevalence of asthma in Uganda: a general population survey. Respir. Res. 19, 184 (2018).
pubmed: 30241519
pmcid: 6151019
doi: 10.1186/s12931-018-0898-5
Munyati, S. S. et al. Chronic cough in primary health care attendees, Harare, Zimbabwe: diagnosis and impact of HIV infection. Clin. Infect. Dis. 40, 1818–1827 (2005).
pubmed: 15909272
doi: 10.1086/429912
Barton, J. H. et al. Adiposity influences airway wall thickness and the asthma phenotype of HIV-associated obstructive lung disease: a cross-sectional study. BMC Pulm. Med. 16, 111 (2016).
pubmed: 27488495
pmcid: 4973076
doi: 10.1186/s12890-016-0274-5
Gingo, M. R. et al. Pulmonary symptoms and diagnoses are associated with HIV in the MACS and WIHS cohorts. BMC Pulm. Med. 14, 75 (2014).
pubmed: 24884738
pmcid: 4021087
doi: 10.1186/1471-2466-14-75
Leung, J. M. et al. The determinants of poor respiratory health status in adults living with human immunodeficiency virus infection. AIDS Patient Care STDS 28, 240–247 (2014).
pubmed: 24742270
doi: 10.1089/apc.2013.0373
Robbins, H. A. et al. Excess cancers among HIV-infected people in the United States. J. Natl Cancer Inst. 107, dju503 (2015).
pubmed: 25663691
pmcid: 4334816
doi: 10.1093/jnci/dju503
Worm, S. W. et al. Non-AIDS defining cancers in the D:A:D Study – time trends and predictors of survival: a cohort study. BMC Infect. Dis. 13, 471 (2013).
pubmed: 24106926
pmcid: 3852673
doi: 10.1186/1471-2334-13-471
Hernández-Ramírez, R. U., Shiels, M. S., Dubrow, R. & Engels, E. A. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV 4, e495–e504 (2017).
pubmed: 28803888
pmcid: 5669995
doi: 10.1016/S2352-3018(17)30125-X
Vandenhende, M.-A. et al. Cancer-related causes of death among HIV-infected patients in France in 2010: evolution since 2000. PLoS ONE 10, e0129550 (2015).
pubmed: 26083524
pmcid: 4470800
doi: 10.1371/journal.pone.0129550
Simard, E. P. & Engels, E. A. Cancer as a cause of death among people with AIDS in the United States. Clin. Infect. Dis. 51, 957–962 (2010).
pubmed: 20825305
doi: 10.1086/656416
Phelps, R. M. et al. Cancer incidence in women with or at risk for HIV. Int. J. Cancer 94, 753–757 (2001).
pubmed: 11745473
doi: 10.1002/ijc.1528
Engels, E. A. et al. Elevated incidence of lung cancer among HIV-infected individuals. J. Clin. Oncol. 24, 1383–1388 (2006).
pubmed: 16549832
doi: 10.1200/JCO.2005.03.4413
Engsig, F. N. et al. Lung cancer in HIV patients and their parents: a Danish cohort study. BMC Cancer 11, 272 (2011).
pubmed: 21702995
pmcid: 3135571
doi: 10.1186/1471-2407-11-272
Clifford, G. M. et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J. Natl Cancer Inst. 97, 425–432 (2005).
pubmed: 15770006
doi: 10.1093/jnci/dji072
Hleyhel, M. et al. Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort. AIDS 28, 2109–2118 (2014).
pubmed: 25265077
doi: 10.1097/QAD.0000000000000382
Shiels, M. S., Cole, S. R., Kirk, G. D. & Poole, C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J. Acquir. Immune Defic. Syndr. 52, 611–622 (2009).
pubmed: 19770804
pmcid: 2790038
doi: 10.1097/QAI.0b013e3181b327ca
Grulich, A. E., van Leeuwen, M. T., Falster, M. O. & Vajdic, C. M. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370, 59–67 (2007).
pubmed: 17617273
doi: 10.1016/S0140-6736(07)61050-2
Shiels, M. S., Cole, S. R., Mehta, S. H. & Kirk, G. D. Lung cancer incidence and mortality among HIV-infected and HIV-uninfected injection drug users. J. Acquir. Immune Defic. Syndr. 55, 510–515 (2010).
pubmed: 20838223
pmcid: 2974802
doi: 10.1097/QAI.0b013e3181f53783
Sigel, K. et al. HIV as an independent risk factor for incident lung cancer. AIDS 26, 1017–1025 (2012).
pubmed: 22382152
doi: 10.1097/QAD.0b013e328352d1ad
Park, L. S., Hernández-Ramírez, R. U., Silverberg, M. J., Crothers, K. & Dubrow, R. Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis. AIDS 30, 273–291 (2016).
pubmed: 26691548
doi: 10.1097/QAD.0000000000000922
Hessol, N. A. et al. Lung cancer incidence and survival among HIV-infected and uninfected women and men. AIDS 29, 1183–1193 (2015).
pubmed: 25888645
doi: 10.1097/QAD.0000000000000690
Shebl, F. M., Engels, E. A., Goedert, J. J. & Chaturvedi, A. K. Pulmonary infections and risk of lung cancer among persons with AIDS. J. Acquir. Immune Defic. Syndr. 55, 375–379 (2010).
pubmed: 20736841
pmcid: 2955766
doi: 10.1097/QAI.0b013e3181eef4f7
Sigel, K. et al. Prognosis in HIV-infected patients with non-small cell lung cancer. Br. J. Cancer 109, 1974–1980 (2013).
pubmed: 24022194
pmcid: 3790190
doi: 10.1038/bjc.2013.545
Hysell, K. et al. Decreased overall survival in HIV-associated non-small-cell lung cancer. Clin. Lung Cancer 22, e498–e505 (2021).
pubmed: 33468393
doi: 10.1016/j.cllc.2020.11.006
Marcus, J. L. et al. Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers. Cancer Epidemiol. Biomark. Prev. 24, 1167–1173 (2015).
doi: 10.1158/1055-9965.EPI-14-1079
Wang, Y.-H. & Shen, X.-D. Human immunodeficiency virus infection and mortality risk among lung cancer patients: a systematic review and meta-analysis. Medicine 97, e0361 (2018).
pubmed: 29642182
pmcid: 5908612
doi: 10.1097/MD.0000000000010361
Stein, L. et al. The spectrum of human immunodeficiency virus-associated cancers in a South African black population: results from a case-control study, 1995-2004. Int. J. Cancer 122, 2260–2265 (2008).
pubmed: 18241034
doi: 10.1002/ijc.23391
Jaquet, A. et al. Cancer and HIV infection in referral hospitals from four West African countries. Cancer Epidemiol. 39, 1060–1065 (2015).
pubmed: 26375806
pmcid: 4679441
doi: 10.1016/j.canep.2015.09.002
Githinji, L. & Zar, H. J. Respiratory complications in children and adolescents with human immunodeficiency virus. Pediatr. Clin. North Am. 68, 131–145 (2021).
pubmed: 33228928
doi: 10.1016/j.pcl.2020.09.016
Frigati, L. J. et al. Chronic comorbidities in children and adolescents with perinatally acquired HIV infection in sub-Saharan Africa in the era of antiretroviral therapy. Lancet Child Adolesc. Health 4, 688–698 (2020).
pubmed: 32359507
doi: 10.1016/S2352-4642(20)30037-7
Moore, D. P. et al. The etiology of pneumonia in HIV-1-infected South African children in the era of antiretroviral treatment: findings from the Pneumonia Etiology Research for Child Health (PERCH) study. Pediatr. Infect. Dis. J. 40, S69–S78 (2021).
pubmed: 34448746
pmcid: 8448402
doi: 10.1097/INF.0000000000002651
Seidenberg, P. et al. The etiology of pneumonia in HIV-infected Zambian children: findings from the Pneumonia Etiology Research for Child Health (PERCH) study. Pediatr. Infect. Dis. J. 40, S50–S58 (2021).
pubmed: 34448744
pmcid: 8448411
doi: 10.1097/INF.0000000000002649
Frigati, L. J. et al. Tuberculosis infection and disease in South African adolescents with perinatally acquired HIV on antiretroviral therapy: a cohort study. J. Int. AIDS Soc. 24, e25671 (2021).
pubmed: 33719199
pmcid: 7957181
doi: 10.1002/jia2.25671
Marangu, D. & Zar, H. J. Childhood pneumonia in low-and-middle-income countries: an update. Paediatr. Respir. Rev. 32, 3–9 (2019).
pubmed: 31422032
pmcid: 6990397
Evans, C., Jones, C. E. & Prendergast, A. J. HIV-exposed, uninfected infants: new global challenges in the era of paediatric HIV elimination. Lancet Infect. Dis. 16, e92–e107 (2016).
pubmed: 27049574
doi: 10.1016/S1473-3099(16)00055-4
Deeks, S. G., Overbaugh, J., Phillips, A. & Buchbinder, S. HIV infection. Nat. Rev. Dis. Primers 1, 15035 (2015).
pubmed: 27188527
doi: 10.1038/nrdp.2015.35
Visseaux, B., Damond, F., Matheron, S., Descamps, D. & Charpentier, C. Hiv-2 molecular epidemiology. Infect. Genet. Evol. 46, 233–240 (2016).
pubmed: 27530215
doi: 10.1016/j.meegid.2016.08.010
Campbell-Yesufu, O. T. & Gandhi, R. T. Update on human immunodeficiency virus (HIV)-2 infection. Clin. Infect. Dis. 52, 780–787 (2011).
pubmed: 21367732
pmcid: 3106263
doi: 10.1093/cid/ciq248
Yuksel, H., Ocalan, M. & Yilmaz, O. E-Cadherin: an important functional molecule at respiratory barrier between defence and dysfunction. Front. Physiol. 12, 720227 (2021).
pubmed: 34671272
pmcid: 8521047
doi: 10.3389/fphys.2021.720227
Brune, K. A. et al. HIV impairs lung epithelial integrity and enters the epithelium to promote chronic lung inflammation. PLoS ONE 11, e0149679 (2016).
pubmed: 26930653
pmcid: 4773117
doi: 10.1371/journal.pone.0149679
Lambert, A. A. et al. A cross sectional analysis of the role of the antimicrobial peptide cathelicidin in lung function impairment within the ALIVE cohort. PLoS ONE 9, e95099 (2014).
pubmed: 24743155
pmcid: 3990590
doi: 10.1371/journal.pone.0095099
Chinnapaiyan, S. et al. HIV infects bronchial epithelium and suppresses components of the mucociliary clearance apparatus. PLoS ONE 12, e0169161 (2017).
pubmed: 28060951
pmcid: 5217953
doi: 10.1371/journal.pone.0169161
Unwalla, H. J., Ivonnet, P., Dennis, J. S., Conner, G. E. & Salathe, M. Transforming growth factor-β1 and cigarette smoke inhibit the ability of β2-agonists to enhance epithelial permeability. Am. J. Respir. Cell Mol. Biol. 52, 65–74 (2015).
pubmed: 24978189
pmcid: 4370252
doi: 10.1165/rcmb.2013-0538OC
Aschner, Y. & Downey, G. P. Transforming growth factor-β: master regulator of the respiratory system in health and disease. Am. J. Respir. Cell Mol. Biol. 54, 647–655 (2016).
pubmed: 26796672
pmcid: 4942197
doi: 10.1165/rcmb.2015-0391TR
Cribbs, S. K., Crothers, K. & Morris, A. Pathogenesis of HIV-related lung disease: immunity, infection, and inflammation. Physiol. Rev. 100, 603–632 (2020).
pubmed: 31600121
doi: 10.1152/physrev.00039.2018
Chinnapaiyan, S. et al. Cigarette smoke promotes HIV infection of primary bronchial epithelium and additively suppresses CFTR function. Sci. Rep. 8, 7984 (2018).
pubmed: 29789655
pmcid: 5964097
doi: 10.1038/s41598-018-26095-z
Schiff, A. E. et al. T cell-tropic HIV efficiently infects alveolar macrophages through contact with infected CD4
pubmed: 33594125
pmcid: 7886866
doi: 10.1038/s41598-021-82066-x
Joshi, P. C., Raynor, R., Fan, X. & Guidot, D. M. HIV-1-transgene expression in rats decreases alveolar macrophage zinc levels and phagocytosis. Am. J. Respir. Cell Mol. Biol. 39, 218–226 (2008).
pubmed: 18314538
pmcid: 2542456
doi: 10.1165/rcmb.2007-0344OC
Akata, K. et al. Altered polarization and impaired phagocytic activity of lung macrophages in people with human immunodeficiency virus and chronic obstructive pulmonary disease. J. Infect. Dis. 225, 862–867 (2022).
pubmed: 34610114
doi: 10.1093/infdis/jiab506
Tachado, S. D., Zhang, J., Zhu, J., Patel, N. & Koziel, H. HIV impairs TNF-α release in response to Toll-like receptor 4 stimulation in human macrophages in vitro. Am. J. Respir. Cell Mol. Biol. 33, 610–621 (2005).
pubmed: 16109884
doi: 10.1165/rcmb.2004-0341OC
Alexandrova, Y., Costiniuk, C. T. & Jenabian, M.-A. Pulmonary immune dysregulation and viral persistence during HIV infection. Front. Immunol. 12, 808722 (2021).
pubmed: 35058937
doi: 10.3389/fimmu.2021.808722
Cribbs, S. K., Lennox, J., Caliendo, A. M., Brown, L. A. & Guidot, D. M. Healthy HIV-1-infected individuals on highly active antiretroviral therapy harbor HIV-1 in their alveolar macrophages. AIDS Res. Hum. Retrovir. 31, 64–70 (2015).
pubmed: 25134819
pmcid: 4287110
doi: 10.1089/aid.2014.0133
Svanberg, C. et al. HIV-1 induction of tolerogenic dendritic cells is mediated by cellular interaction with suppressive T cells. Front. Immunol. 13, 790276 (2022).
pubmed: 36032117
pmcid: 9399885
doi: 10.3389/fimmu.2022.790276
Gaiha, G. D. et al. Surfactant protein A binds to HIV and inhibits direct infection of CD4
pubmed: 18566427
doi: 10.4049/jimmunol.181.1.601
Madsen, J. et al. Surfactant protein D modulates HIV infection of both T-cells and dendritic cells. PLoS ONE 8, e59047 (2013).
pubmed: 23527085
pmcid: 3601116
doi: 10.1371/journal.pone.0059047
Doitsh, G. et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 505, 509–514 (2014).
pubmed: 24356306
pmcid: 4047036
doi: 10.1038/nature12940
Neff, C. P. et al. Lymphocytic alveolitis is associated with the accumulation of functionally impaired HIV-specific T cells in the lung of antiretroviral therapy-naive subjects. Am. J. Respir. Crit. Care Med. 191, 464–473 (2015).
pubmed: 25536276
pmcid: 4351596
doi: 10.1164/rccm.201408-1521OC
Moir, S. & Fauci, A. S. B cells in HIV infection and disease. Nat. Rev. Immunol. 9, 235–245 (2009).
pubmed: 19319142
pmcid: 2779527
doi: 10.1038/nri2524
Morris, D. et al. Unveiling the mechanisms for decreased glutathione in individuals with HIV infection. Clin. Dev. Immunol. 2012, 734125 (2012).
pubmed: 22242038
doi: 10.1155/2012/734125
Ivanov, A. V. et al. Oxidative stress during HIV infection: mechanisms and consequences. Oxid. Med. Cell. Longev. 2016, 8910396 (2016).
pubmed: 27829986
pmcid: 5088339
doi: 10.1155/2016/8910396
Mandas, A. et al. Oxidative imbalance in HIV-1 infected patients treated with antiretroviral therapy. J. Biomed. Biotechnol. 2009, 749575 (2009).
pubmed: 19884983
pmcid: 2768042
doi: 10.1155/2009/749575
Cribbs, S. K., Guidot, D. M., Martin, G. S., Lennox, J. & Brown, L. A. Anti-retroviral therapy is associated with decreased alveolar glutathione levels even in healthy HIV-infected individuals. PLoS ONE 9, e88630 (2014).
pubmed: 24533122
pmcid: 3922940
doi: 10.1371/journal.pone.0088630
Yeligar, S. M. et al. Dysregulation of alveolar macrophage PPARγ, NADPH oxidases, and TGFβ1 in otherwise healthy HIV-infected individuals. AIDS Res. Hum. Retrovir. 33, 1018–1026 (2017).
pubmed: 28314381
pmcid: 5650722
doi: 10.1089/aid.2016.0030
Lassiter, C. et al. HIV-1 transgene expression in rats causes oxidant stress and alveolar epithelial barrier dysfunction. AIDS Res. Ther. 6, 1 (2009).
pubmed: 19193217
pmcid: 2644707
doi: 10.1186/1742-6405-6-1
Staitieh, B. S. et al. HIV-1 decreases Nrf2/ARE activity and phagocytic function in alveolar macrophages. J. Leukoc. Biol. 102, 517–525 (2017).
pubmed: 28550120
pmcid: 5505750
doi: 10.1189/jlb.4A0616-282RR
Kukoyi, A. T. et al. MiR-144 mediates Nrf2 inhibition and alveolar epithelial dysfunction in HIV-1 transgenic rats. Am. J. Physiol., Cell Physiol. 317, C390–C397 (2019).
pubmed: 31091144
doi: 10.1152/ajpcell.00038.2019
Wang, T. et al. Transfer of intracellular HIV Nef to endothelium causes endothelial dysfunction. PLoS ONE 9, e91063 (2014).
pubmed: 24608713
pmcid: 3946685
doi: 10.1371/journal.pone.0091063
Kanmogne, G. D., Primeaux, C. & Grammas, P. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem. Biophys. Res. Commun. 333, 1107–1115 (2005).
pubmed: 15979050
doi: 10.1016/j.bbrc.2005.05.198
Spikes, L. et al. Enhanced pulmonary arteriopathy in simian immunodeficiency virus-infected macaques exposed to morphine. Am. J. Respir. Crit. Care Med. 185, 1235–1243 (2012).
pubmed: 22447963
pmcid: 3373069
doi: 10.1164/rccm.201110-1909OC
Jacob, B. A. et al. HIV-1-induced pulmonary oxidative and nitrosative stress: exacerbated response to endotoxin administration in HIV-1 transgenic mouse model. Am. J. Physiol. Lung Cell. Mol. Physiol. 291, L811–L819 (2006).
pubmed: 16728526
doi: 10.1152/ajplung.00468.2005
Cole, S. B. et al. Oxidative stress and antioxidant capacity in smoking and nonsmoking men with HIV/acquired immunodeficiency syndrome. Nutr. Clin. Pract. 20, 662–667 (2005).
pubmed: 16306304
doi: 10.1177/0115426505020006662
Pacht, E. R., Diaz, P., Clanton, T., Hart, J. & Gadek, J. E. Alveolar fluid glutathione decreases in asymptomatic HIV-seropositive subjects over time. Chest 112, 785–788 (1997).
pubmed: 9315816
doi: 10.1378/chest.112.3.785
Morris, A. et al. Comparison of the respiratory microbiome in healthy nonsmokers and smokers. Am. J. Respir. Crit. Care Med. 187, 1067–1075 (2013).
pubmed: 23491408
pmcid: 3734620
doi: 10.1164/rccm.201210-1913OC
Segal, L. N. et al. Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype. Nat. Microbiol. 1, 16031 (2016).
pubmed: 27572644
pmcid: 5010013
doi: 10.1038/nmicrobiol.2016.31
Beck, J. M. et al. Multicenter comparison of lung and oral microbiomes of HIV-infected and HIV-uninfected individuals. Am. J. Respir. Crit. Care Med. 192, 1335–1344 (2015).
pubmed: 26247840
pmcid: 4731698
doi: 10.1164/rccm.201501-0128OC
Cui, L. et al. Topographic diversity of the respiratory tract mycobiome and alteration in HIV and lung disease. Am. J. Respir. Crit. Care Med. 191, 932–942 (2015).
pubmed: 25603113
pmcid: 4435454
doi: 10.1164/rccm.201409-1583OC
Lozupone, C. et al. Widespread colonization of the lung by Tropheryma whipplei in HIV infection. Am. J. Respir. Crit. Care Med. 187, 1110–1117 (2013).
pubmed: 23392441
pmcid: 3734615
doi: 10.1164/rccm.201211-2145OC
Morris, A. et al. Longitudinal analysis of the lung microbiota of cynomolgous macaques during long-term SHIV infection. Microbiome 4, 38 (2016).
pubmed: 27391224
pmcid: 4939015
doi: 10.1186/s40168-016-0183-0
Zhou, J. J. et al. Supraglottic lung microbiome taxa are associated with pulmonary abnormalities in an HIV longitudinal cohort. Am. J. Respir. Crit. Care Med. 202, 1727–1731 (2020).
pubmed: 32783620
pmcid: 7737582
doi: 10.1164/rccm.202004-1086LE
Yang, L. et al. Alterations in oral microbiota in HIV are related to decreased pulmonary function. Am. J. Respir. Crit. Care Med. 201, 445–457 (2020).
pubmed: 31682463
pmcid: 7049920
doi: 10.1164/rccm.201905-1016OC
Nazli, A. et al. Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog. 6, e1000852 (2010).
pubmed: 20386714
pmcid: 2851733
doi: 10.1371/journal.ppat.1000852
Estes, J. D. et al. Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog. 6, e1001052 (2010).
pubmed: 20808901
pmcid: 2924359
doi: 10.1371/journal.ppat.1001052
Brenchley, J. M. Mucosal immunity in human and simian immunodeficiency lentivirus infections. Mucosal Immunol. 6, 657–665 (2013).
pubmed: 23549448
pmcid: 4154146
doi: 10.1038/mi.2013.15
He, S. et al. A systematic review and meta-analysis of diagnostic accuracy of serum 1,3-β-D-glucan for invasive fungal infection: focus on cutoff levels. J. Microbiol. Immunol. Infect. 48, 351–361 (2015).
pubmed: 25081986
doi: 10.1016/j.jmii.2014.06.009
Morris, A. et al. Serum (1→3)-β-D-glucan levels in HIV-infected individuals are associated with immunosuppression, inflammation, and cardiopulmonary function. J. Acquir. Immune Defic. Syndr. 61, 462–468 (2012).
pubmed: 22972021
pmcid: 3494803
doi: 10.1097/QAI.0b013e318271799b
Hameiri Bowen, D. et al. Cytomegalovirus-specific immunoglobulin G is associated with chronic lung disease in children and adolescents from sub-Saharan Africa Living with perinatal human immunodeficiency virus. Clin. Infect. Dis. 73, e264–e266 (2021).
pubmed: 33242076
doi: 10.1093/cid/ciaa1757
Nenna, R. et al. High cytomegalovirus serology and subsequent COPD-related mortality: a longitudinal study. ERJ Open Res. 6, 00062 (2020).
pubmed: 32363208
pmcid: 7184115
doi: 10.1183/23120541.00062-2020
Nenna, R. et al. Cytomegalovirus serology in young to mid-adult life and decline of lung function. Clin. Respir. J. https://doi.org/10.1111/crj.13600 (2023).
doi: 10.1111/crj.13600
pubmed: 36924061
pmcid: 10214568
Ahlström, M. G. et al. Association between smoking status assessed with plasma-cotinine and inflammatory and endothelial biomarkers in HIV-positive and HIV-negative individuals. HIV Med. 19, 679–687 (2018).
pubmed: 29984882
doi: 10.1111/hiv.12647
Poudel, K. C., Poudel-Tandukar, K., Bertone-Johnson, E. R., Pekow, P. & Vidrine, D. J. Inflammation in relation to intensity and duration of cigarette smoking among people living with HIV. AIDS Behav. 25, 856–865 (2021).
pubmed: 32986190
doi: 10.1007/s10461-020-03048-0
Neff, C. P. et al. HIV infection is associated with loss of anti-inflammatory alveolar macrophages. J. Immunol. 205, 2447–2455 (2020).
pubmed: 32929038
doi: 10.4049/jimmunol.2000361
Corleis, B. et al. Smoking and human immunodeficiency virus 1 infection promote retention of CD8
pubmed: 34166603
pmcid: 8641855
doi: 10.1165/rcmb.2021-0168OC
Staitieh, B. S. et al. HIV increases the risk of cigarette smoke-induced emphysema via MMP-9. J. Acquir. Immune Defic. Syndr. https://doi.org/10.1097/QAI.0000000000003125 (2022).
doi: 10.1097/QAI.0000000000003125
pubmed: 36331810
pmcid: 9911107
Nieman, R. B., Fleming, J., Coker, R. J., Harris, J. R. & Mitchell, D. M. The effect of cigarette smoking on the development of AIDS in HIV-1-seropositive individuals. AIDS 7, 705–710 (1993).
pubmed: 8318178
doi: 10.1097/00002030-199305000-00015
Feldman, J. G. et al. Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the Women’s Interagency HIV study. Am. J. Public Health 96, 1060–1065 (2006).
pubmed: 16670229
pmcid: 1470629
doi: 10.2105/AJPH.2005.062745
Winhusen, T. et al. Baseline cigarette smoking status as a predictor of virologic suppression and CD4 cell count during one-year follow-up in substance users with uncontrolled HIV infection. AIDS Behav. 22, 2026–2032 (2018).
pubmed: 29030717
pmcid: 5899070
doi: 10.1007/s10461-017-1928-x
Brown, J. L. et al. The association between cigarette smoking, virologic suppression, and CD4
pubmed: 28497980
pmcid: 6092924
doi: 10.1080/09540121.2017.1327645
Akhtar-Khaleel, W. Z. et al. Trends and predictors of cigarette smoking among HIV seropositive and seronegative men: the multicenter aids cohort study. AIDS Behav. 20, 622–632 (2016).
pubmed: 26093780
pmcid: 4760908
doi: 10.1007/s10461-015-1099-6
Jones, T. P. W. et al. Alcohol, smoking, recreational drug use and association with virological outcomes among people living with HIV: cross-sectional and longitudinal analyses. HIV Med. 23, 209–226 (2022).
pubmed: 34634176
doi: 10.1111/hiv.13156
Cyktor, J. et al. Associations of HIV persistence, cigarette smoking, inflammation, and pulmonary dysfunction in people with HIV on antiretroviral therapy. Medicine 101, e29264 (2022).
pubmed: 35801755
pmcid: 9259161
doi: 10.1097/MD.0000000000029264
Clarke, J. R. et al. The epidemiology of HIV-1 infection of the lung in AIDS patients. AIDS 7, 555–560 (1993).
pubmed: 8099490
doi: 10.1097/00002030-199304000-00015
Ranjit, S., Sinha, N., Kodidela, S. & Kumar, S. Benzo(a)pyrene in cigarette smoke enhances HIV-1 replication through NF-κB activation via CYP-mediated oxidative stress pathway. Sci. Rep. 8, 10394 (2018).
pubmed: 29991690
pmcid: 6039513
doi: 10.1038/s41598-018-28500-z
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease https://goldcopd.org/wp-content/uploads/2022/12/GOLD-2023-ver-1.1-2Dec2022_WMV.pdf (2023).
US Preventive Services Task Force. Screening for chronic obstructive pulmonary disease: US Preventive Services Task Force reaffirmation recommendation statement. J. Am. Med. Assoc. 327, 1806–1811 (2022).
doi: 10.1001/jama.2022.5692
Lambert, A. A. et al. Implementation of a COPD screening questionnaire in an outpatient HIV clinic. Chron. Obstruct. Pulmon. Dis. 13, 767–772 (2016).
doi: 10.3109/15412555.2016.1161016
Schnieders, E. et al. Performance of alternative COPD case-finding tools: a systematic review and meta-analysis. Eur. Respir. Rev. 30, 200350 (2021).
pubmed: 34039672
pmcid: 9488779
doi: 10.1183/16000617.0350-2020
MacDonald, D. M. et al. Smoking and accelerated lung function decline in HIV-positive individuals: a secondary analysis of the START pulmonary substudy. J. Acquir. Immune Defic. Syndr. 79, e85–e92 (2018).
pubmed: 29985804
pmcid: 6350922
doi: 10.1097/QAI.0000000000001797
Fan, H. et al. Pulmonary tuberculosis as a risk factor for chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ann. Transl Med. 9, 390 (2021).
pubmed: 33842611
pmcid: 8033376
doi: 10.21037/atm-20-4576
Global Initiative for Asthma. Global strategy for asthma management and prevention. Global Initiative for Asthma https://ginasthma.org/wp-content/uploads/2022/07/GINA-Main-Report-2022-FINAL-22-07-01-WMS.pdf (2022).
Pekkanen, J. & Pearce, N. Defining asthma in epidemiological studies. Eur. Respir. J. 14, 951–957 (1999).
pubmed: 10573248
doi: 10.1034/j.1399-3003.1999.14d37.x
Weakley, J. et al. Agreement between obstructive airways disease diagnoses from self-report questionnaires and medical records. Prev. Med. 57, 38–42 (2013).
pubmed: 23597657
doi: 10.1016/j.ypmed.2013.04.001
Coghill, A. E. et al. Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National Cancer Data Base. Cancer 125, 2868–2876 (2019).
pubmed: 31050361
Shiels, M. S., Pfeiffer, R. M. & Engels, E. A. Age at cancer diagnosis among persons with AIDS in the United States. Ann. Intern. Med. 153, 452–460 (2010).
pubmed: 20921544
pmcid: 3071616
doi: 10.7326/0003-4819-153-7-201010050-00008
Rengan, R., Mitra, N., Liao, K., Armstrong, K. & Vachani, A. Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study. Lancet Oncol. 13, 1203–1209 (2012).
pubmed: 23164952
doi: 10.1016/S1470-2045(12)70466-7
Shuter, J., Reddy, K. P., Hyle, E. P., Stanton, C. A. & Rigotti, N. A. Harm reduction for smokers living with HIV. Lancet HIV 8, e652–e658 (2021).
pubmed: 34461050
pmcid: 8484051
doi: 10.1016/S2352-3018(21)00156-9
National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365, 395–409 (2011).
doi: 10.1056/NEJMoa1102873
Kong, C. Y. et al. Benefits and harms of lung cancer screening in HIV-infected individuals with CD4
pubmed: 29683843
doi: 10.1097/QAD.0000000000001818
US Preventive Services Task Force. Screening for lung cancer: US Preventive Services Task Force recommendation statement. J. Am. Med. Assoc. 325, 962–970 (2021).
doi: 10.1001/jama.2021.1117
Sellers, S. A. et al. Optimal lung cancer screening criteria among persons living with HIV. J. Acquir. Immune Defic. Syndr. 90, 184–192 (2022).
pubmed: 35125470
pmcid: 9203877
doi: 10.1097/QAI.0000000000002930
World Health Organization. Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach (WHO, 2021).
Frigati, L. J. et al. The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting. Thorax 66, 496–501 (2011).
pubmed: 21460373
doi: 10.1136/thx.2010.156752
World Health Organization. WHO Consolidated Guidelines on Tuberculosis: Module 5: Management of Tuberculosis in Children and Adolescents (WHO, 2022).
Githinji, L. N., Gray, D. M., Hlengwa, S., Myer, L. & Zar, H. J. Lung function in South African adolescents infected perinatally with HIV and treated long-term with antiretroviral therapy. Ann. Am. Thorac. Soc. 14, 722–729 (2017).
pubmed: 28248548
pmcid: 5427744
doi: 10.1513/AnnalsATS.201612-1018OC
European AIDS Clinical Society. Guidelines, version 11.1. EACS https://www.eacsociety.org/media/guidelines-11.1_final_09-10.pdf (2022).
Nahid, P. et al. Executive summary: official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. Clin. Infect. Dis. 63, 853–867 (2016).
pubmed: 27621353
pmcid: 6366011
doi: 10.1093/cid/ciw566
Dorman, S. E. et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N. Engl. J. Med. 384, 1705–1718 (2021).
pubmed: 33951360
pmcid: 8282329
doi: 10.1056/NEJMoa2033400
Lam, J. O. et al. Smoking and cessation treatment among persons with and without HIV in a US integrated health system. Drug Alcohol. Depend. 213, 108128 (2020).
pubmed: 32603975
pmcid: 7392076
doi: 10.1016/j.drugalcdep.2020.108128
Pool, E. R. M., Dogar, O., Lindsay, R. P., Weatherburn, P. & Siddiqi, K. Interventions for tobacco use cessation in people living with HIV and AIDS. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD011120.pub2 (2016).
doi: 10.1002/14651858.CD011120.pub2
pubmed: 27292836
pmcid: 8604206
Uthman, O. A. et al. Comparison of mHealth and face-to-face interventions for smoking cessation among people living with HIV: meta-analysis. JMIR Mhealth Uhealth 7, e203 (2019).
pubmed: 30617044
pmcid: 6329415
doi: 10.2196/mhealth.9329
Mann-Jackson, L. et al. A qualitative systematic review of cigarette smoking cessation interventions for persons living with HIV. J. Cancer Educ. 34, 1045–1058 (2019).
pubmed: 31037506
pmcid: 6819245
doi: 10.1007/s13187-019-01525-2
Oshagbemi, O. A., Odiba, J. O., Daniel, A. & Yunusa, I. Absolute blood eosinophil counts to guide inhaled corticosteroids therapy among patients with COPD: systematic review and meta-analysis. Curr. Drug Targets 20, 1670–1679 (2019).
pubmed: 31393244
doi: 10.2174/1389450120666190808141625
Harries, T. H. et al. Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis. Respir. Res. 21, 3 (2020).
pubmed: 31900184
pmcid: 6942335
doi: 10.1186/s12931-019-1268-7
Miravitlles, M. et al. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. Eur. Respir. Rev. 30, 210075 (2021).
pubmed: 34168063
pmcid: 9488732
doi: 10.1183/16000617.0075-2021
Dong, Y. H. et al. Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: a systematic review and meta-analysis of randomized controlled trials. Chest 145, 1286–1297 (2014).
pubmed: 24504044
doi: 10.1378/chest.13-2137
Chapman, K. R. et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am. J. Respir. Crit. Care Med. 198, 329–339 (2018).
pubmed: 29779416
doi: 10.1164/rccm.201803-0405OC
Rogliani, P., Ritondo, B. L., Gabriele, M., Cazzola, M. & Calzetta, L. Optimizing de-escalation of inhaled corticosteroids in COPD: a systematic review of real-world findings. Expert Rev. Clin. Pharmacol. 13, 977–990 (2020).
pubmed: 32885691
doi: 10.1080/17512433.2020.1817739
Boyd, S. D. et al. Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone. J. Acquir. Immune Defic. Syndr. 63, 355–361 (2013).
pubmed: 23535292
pmcid: 3683093
doi: 10.1097/QAI.0b013e31829260d6
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Clinical Info HIV.gov https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv (2023).
Sigel, K. M. et al. Short-term outcomes for lung cancer resection surgery in HIV infection. AIDS 33, 1353–1360 (2019).
pubmed: 30889013
doi: 10.1097/QAD.0000000000002200
Makinson, A. et al. Risks of opportunistic infections in people with human immunodeficiency virus with cancers treated with chemotherapy. Open Forum Infect. Dis. 8, ofab389 (2021).
pubmed: 34458394
pmcid: 8391784
doi: 10.1093/ofid/ofab389
Uldrick, T. S. et al. Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer – a phase 1 study. JAMA Oncol. 5, 1332–1339 (2019).
pubmed: 31154457
pmcid: 6547135
doi: 10.1001/jamaoncol.2019.2244
Peluso, M. J. et al. Outcomes of immunomodulatory and biologic therapy in people living with HIV. AIDS 34, 1171–1179 (2020).
pubmed: 32310901
doi: 10.1097/QAD.0000000000002549
Grover, S. et al. Reduced cancer survival among adults with HIV and AIDS-defining illnesses despite no difference in cancer stage at diagnosis. J. Acquir. Immune Defic. Syndr. 79, 421–429 (2018).
pubmed: 30211722
pmcid: 6203623
doi: 10.1097/QAI.0000000000001842
World Health Organization. Revised WHO classification and treatment of childhood pneumonia at health facilities: evidence summaries. WHO https://apps.who.int/iris/bitstream/handle/10665/137319/9789241507813_eng.pdf (2014).
Punpanich, W., Groome, M., Muhe, L., Qazi, S. A. & Madhi, S. A. Systematic review on the etiology and antibiotic treatment of pneumonia in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 30, e192–202 (2011).
pubmed: 21857264
doi: 10.1097/INF.0b013e31822d989c
Turkova, A. et al. Shorter treatment for non-severe tuberculosis in African and Indian children. N. Engl. J. Med. 386, 911–922 (2022).
pubmed: 35263517
pmcid: 7612496
doi: 10.1056/NEJMoa2104535
Price, A. et al. Effect of azithromycin on incidence of acute respiratory exacerbations in children with HIV taking antiretroviral therapy and co-morbid chronic lung disease: a secondary analysis of the BREATHE trial. eClinicalMedicine 42, 101195 (2021).
pubmed: 34820609
pmcid: 8599092
doi: 10.1016/j.eclinm.2021.101195
Rubinstein, A., Bernstein, L. J., Charytan, M., Krieger, B. Z. & Ziprkowski, M. Corticosteroid treatment for pulmonary lymphoid hyperplasia in children with the acquired immune deficiency syndrome. Pediatr. Pulmonol. 4, 13–17 (1988).
pubmed: 2449650
doi: 10.1002/ppul.1950040105
Sabin, C. A. et al. Respiratory symptoms and chronic bronchitis in people with and without HIV infection. HIV Med. 22, 11–21 (2021).
pubmed: 32892488
doi: 10.1111/hiv.12955
Brown, J. et al. Respiratory symptoms in people living with HIV and the effect of antiretroviral therapy: a systematic review and meta-analysis. Thorax 72, 355–366 (2017).
pubmed: 27965402
doi: 10.1136/thoraxjnl-2016-208657
Kunisaki, K. M. et al. Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial. Lancet Respir. Med. 4, 980–989 (2016).
pubmed: 27773665
pmcid: 5279910
doi: 10.1016/S2213-2600(16)30319-8
Terry, C. et al. Dyspnea and pulmonary function among participants in the multicenter AIDS cohort study using protease inhibitors: a cross-sectional study. AIDS Res. Hum. Retrovir. 38, 143–151 (2022).
pubmed: 34969258
pmcid: 8861940
doi: 10.1089/aid.2021.0082
Khoury, A. L. et al. Diminished physical function in older HIV-infected adults in the Southeastern U.S. despite successful antiretroviral therapy. PLoS ONE 12, e0179874 (2017).
pubmed: 28662079
pmcid: 5491055
doi: 10.1371/journal.pone.0179874
Robertson, T. E. et al. HIV infection is an independent risk factor for decreased 6-minute walk test distance. PLoS ONE 14, e0212975 (2019).
pubmed: 31017909
pmcid: 6481785
doi: 10.1371/journal.pone.0212975
Campo, M. et al. Association of chronic cough and pulmonary function with 6-minute walk test performance in HIV infection. J. Acquir. Immune Defic. Syndr. 65, 557–563 (2014).
pubmed: 24346638
pmcid: 4405108
doi: 10.1097/QAI.0000000000000086
Triplette, M. et al. The differential impact of emphysema on respiratory symptoms and 6-minute walk distance in HIV infection. J. Acquir. Immune Defic. Syndr. 74, e23–e29 (2017).
pubmed: 27716727
pmcid: 5140705
doi: 10.1097/QAI.0000000000001133
Chen, Y. et al. Human immunodeficiency virus infection and incident heart failure: a meta-analysis of prospective studies. J. Acquir. Immune Defic. Syndr. 87, 741–749 (2021).
pubmed: 33492019
doi: 10.1097/QAI.0000000000002629
Wolff, A. J. & O’Donnell, A. E. Pulmonary effects of illicit drug use. Clin. Chest Med. 25, 203–216 (2004).
pubmed: 15062611
doi: 10.1016/S0272-5231(03)00137-0
Metlay, J. P. et al. Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am. J. Respir. Crit. Care Med. 200, e45–e67 (2019).
pubmed: 31573350
pmcid: 6812437
doi: 10.1164/rccm.201908-1581ST
Jan, A. K. et al. Markers of inflammation and immune activation are associated with lung function in a multi-center cohort of persons with HIV. AIDS 35, 1031–1040 (2021).
pubmed: 33635847
doi: 10.1097/QAD.0000000000002846
de Koning, H. J. et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N. Engl. J. Med. 382, 503–513 (2020).
pubmed: 31995683
doi: 10.1056/NEJMoa1911793
Matthay, M. A. et al. Acute respiratory distress syndrome. Nat. Rev. Dis. Primers 5, 18 (2019).
pubmed: 30872586
pmcid: 6709677
doi: 10.1038/s41572-019-0069-0
Hewitt, R. J. & Lloyd, C. M. Regulation of immune responses by the airway epithelial cell landscape. Nat. Rev. Immunol. 21, 347–362 (2021).
pubmed: 33442032
pmcid: 7804588
doi: 10.1038/s41577-020-00477-9